Santen Pharmaceutical Co., Ltd.

4536

JP3336000009

SANTEN PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and sales of pharmaceutical products. The Company has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The Company engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The Company operates in Japan, Europe, Asia, North America markets.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Santen Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,512 JPY

Average target price

1,767 JPY

Spread / Average Target

+16.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANTEN PHARMACEUTICAL CO., LTD.	+7.65%	3.5B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
1,512 ^JPY	+1.41%		+4.13%	+7.65%

Mar. 26	Santen Pharmaceutical to Cancel 12 Million Treasury Shares	MT
Mar. 25	Santen Announces Re-Designation Akira Kurokawa as Director of the Board and Chairman from Representative Director of the Board, Chairman, Effective from April 1, 2024	CI

Santen Pharmaceutical to Cancel 12 Million Treasury Shares	Mar. 25	MT
Santen Announces Re-Designation Akira Kurokawa as Director of the Board and Chairman from Representative Director of the Board, Chairman, Effective from April 1, 2024	Mar. 25	CI
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.	Mar. 25	CI
Santen Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 11, 2023, has closed with 12,571,400 shares, representing 3.38% for ¥16,178.35 million.	Mar. 21	CI
Santen Pharmaceutical's Returns to the Black in Fiscal Nine Months	Feb. 08	MT
Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024	Feb. 08	CI
Jefferies Adjusts Santen Pharmaceutical’s Price Target to 1,700 Yen From 1,650 Yen, Keeps at Buy	Jan. 29	MT
Santen Pharmaceutical Further Repurchases Shares for Over 1 Billion Yen	Jan. 07	MT
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.	Jan. 05	CI
Santen Pharmaceutical Buys Back Nearly 2 Billion Yen of Shares	Dec. 04	MT
Santen Pharmaceutical’s Fiscal H1 EPS Increases to 69.68 Yen as Net Sales Rise 13.1% to 145.81 Billion Yen; Declares Interim Dividend of 16 Yen Per Share, Maintains Forecast	Nov. 08	MT
Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024	Nov. 07	CI
Santen Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on November 30, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	Nov. 07	CI
Santen Pharmaceutical Buys Back 523,400 shares for 772.6 Million Yen in September	23-10-02	MT
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.	23-10-02	CI
Jefferies Adjusts Santen Pharmaceutical’s Price Target to 1,650 Yen From 1,400 Yen, Keeps at Buy	23-09-21	MT
Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024	23-09-19	CI
Santen Pharmaceutical Co., Ltd. Provides Dividend Forecasts for Second Quarter of 2024 and the Fiscal Year Ending March 31, 2024	23-08-03	CI
Santen Pharmaceutical Co., Ltd. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024	23-08-03	CI
Santen Disposes of Shares as Restricted Stock-Linked Remuneration/Restricted Stock	23-07-24	MT
Visiox Pharma Enters into A Definitive Agreement with Santen Pharmaceutical Co., Ltd to License OMLONTI	23-07-19	CI
Bank Earnings Leave Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday	23-07-19	MT
Harrow Health Acquires Certain US, Canada Rights to Santen Pharmaceutical's Ophthalmic Portfolio	23-07-19	MT
Santen Pharmaceutical Co., Ltd. Signs Licensing Agreements	23-07-18	CI
Jefferies Adjusts Santen Pharmaceutical's Price Target to 1,400 Yen From 1,300 Yen, Keeps at Buy	23-07-12	MT